Presentation Title

P-19 Anticancer Activity of Heteroaromatic Cyanostilbenes

Presenter Information

Joshua RotichFollow

Presenter Status

Biology

Preferred Session

Poster Session

Start Date

25-10-2019 2:00 PM

Presentation Abstract

Cancer is currently the second leading killer disease. There are many different kinds of cancer that are associated with almost every organ in the human body (e.g., brain cancer, colon cancer, breast cancer, prostate cancer, blood cancer, lung cancer, etc.).

In the Biology Department, Dr. Smith and Dr. Murray are researching glioblastoma brain cancer cells. Glioblastoma is a very invasive cancer that is highly lethal. Chances of not surviving when its at stage four is more than 98%. Detecting this cancer while it is developing is difficult because symptoms are mild headache, fatigue, nausea and slight loss of weight. By the time one gets blurred vision, the cancer is already at stage four, and at this stage, it generally kills in less than three months if not treated and in thirteen months if treated.

The major challenge with this type of cancer is that it cannot be treated using chemotherapy or radiotherapy. Furthermore, it is aggressively invasive. To date, there is no cure, and not more than 3% of those diagnosed have lived more than three years.

There are compounds which have shown anticancer invasion properties. Some include stilbene, benzoamidazole and benzothiazole acetonitrlile. In my research, I will be synthesizing a hybrid drug⁠—hybrid because it is made of two compounds which have shown anticancer invasion activity. Once I synthesize the drug, I will use glioblastoma cells in the lab to test the activity of the drug.

This document is currently not available here.

Share

COinS
 
Oct 25th, 2:00 PM

P-19 Anticancer Activity of Heteroaromatic Cyanostilbenes

Cancer is currently the second leading killer disease. There are many different kinds of cancer that are associated with almost every organ in the human body (e.g., brain cancer, colon cancer, breast cancer, prostate cancer, blood cancer, lung cancer, etc.).

In the Biology Department, Dr. Smith and Dr. Murray are researching glioblastoma brain cancer cells. Glioblastoma is a very invasive cancer that is highly lethal. Chances of not surviving when its at stage four is more than 98%. Detecting this cancer while it is developing is difficult because symptoms are mild headache, fatigue, nausea and slight loss of weight. By the time one gets blurred vision, the cancer is already at stage four, and at this stage, it generally kills in less than three months if not treated and in thirteen months if treated.

The major challenge with this type of cancer is that it cannot be treated using chemotherapy or radiotherapy. Furthermore, it is aggressively invasive. To date, there is no cure, and not more than 3% of those diagnosed have lived more than three years.

There are compounds which have shown anticancer invasion properties. Some include stilbene, benzoamidazole and benzothiazole acetonitrlile. In my research, I will be synthesizing a hybrid drug⁠—hybrid because it is made of two compounds which have shown anticancer invasion activity. Once I synthesize the drug, I will use glioblastoma cells in the lab to test the activity of the drug.